Midostaurin

Introduction Overview

Generic Name

midostaurin

Brand Name

Rydapt

Dosage Form

oral capsule

Drug Class

Multikinase inhibitors

Pharmacokinetics

Absorption:
Midostaurin exhibits oral bioavailability when administered as capsules. The drug is absorbed in the gastrointestinal tract, with administration recommended twice daily with food to enhance absorption and reduce gastrointestinal irritation. Peak plasma concentrations are typically reached within a few hours after dosing. Food intake is essential as it significantly improves midostaurin's absorption, with fasting reducing bioavailability. Studies indicate that midostaurin demonstrates a prolonged absorption phase suggesting sustained systemic exposure.

Distribution:
Once absorbed, midostaurin has a large volume of distribution, reflective of extensive tissue penetration. Protein binding is high, with midostaurin extensively bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. This extensive distribution facilitates drug access to target tissues, including bone marrow and blood compartments relevant for therapeutic efficacy against hematologic malignancies.

Metabolism:
Midostaurin undergoes extensive hepatic metabolism predominantly via cytochrome P450 3A4 (CYP3A4) isoenzyme pathways. It is metabolized into several active metabolites, including CGP52421 and CGP62221, which contribute to pharmacologic activity. The complex metabolic pattern results in a multi-phasic elimination profile. Concomitant use of strong CYP3A4 inhibitors or inducers significantly affects midostaurin plasma levels, necessitating dosage adjustments or monitoring.

Elimination:
Elimination of midostaurin and its metabolites occurs primarily through fecal excretion, with minimal renal clearance. The terminal half-life of midostaurin is variable but generally prolonged, owing to the formation of active metabolites with longer half-lives. This pharmacokinetic profile underpins the twice-daily dosing schedule to maintain steady-state systemic concentrations. Clinical monitoring of liver function is advised due to hepatic metabolism and potential accumulation in cases of hepatic impairment.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 25 mg

Dosages for Adults and Adolescents:
- For acute myeloid leukemia (AML) patients with FLT3 mutation, midostaurin is administered at 50 mg orally twice daily (approximately every 12 hours) on Days 8 to 21 of each induction and consolidation chemotherapy cycle.
- For patients with systemic mastocytosis, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL), the dose is 100 mg orally twice daily, administered continuously until disease progression or unacceptable toxicity.

Specific Patient Populations:
- Pediatric patients under 18 years old: Rydapt is not approved.
- Patients with hepatic impairment: No specific dosing recommendations but caution is advised due to hepatic metabolism.
- Pregnant women: Contraindicated due to teratogenicity risks.
- Patients of reproductive potential: Effective contraception is required during treatment and for at least 4 months after the last dose.

Clinical Guidelines:
- Monitoring for toxicity is recommended especially during the initial weeks: weekly for the first 4 weeks, every other week for the following 8 weeks, and then monthly thereafter.
- Administration should consistently be with food to optimize absorption.
- Capsules must be swallowed whole; crushing or opening capsules is contraindicated to avoid altered pharmacokinetics and reduced efficacy.

Mechanism Of Action

Midostaurin is a potent multikinase inhibitor that exerts its therapeutic effect by targeting and inhibiting multiple receptor tyrosine kinases critical in the pathogenesis of certain hematologic malignancies. The primary molecular target is the FMS-like tyrosine kinase 3 (FLT3) receptor, including both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutants. By inhibiting FLT3 phosphorylation, midostaurin disrupts downstream signaling pathways responsible for leukemic cell proliferation, survival, and differentiation blockade.

At the cellular level, midostaurin inhibits several other kinases, including KIT, PDGFR, VEGFR, and protein kinase C isoforms, contributing to its antileukemic and antimastocytosis effects. This multitarget profile facilitates suppression of aberrant signaling cascades like PI3K/AKT, RAS/RAF/MEK/ERK, and STAT5 pathways, which are vital for malignant hematopoietic cell growth.

Biochemically, midostaurin binds competitively at the ATP-binding site of these kinases, stabilizing them in an inactive conformation and thereby preventing phosphorylation and activation. This leads to induction of apoptosis and inhibition of proliferation of malignant cells. The drug's active metabolites further enhance this inhibitory effect, prolonging therapeutic activity.

Clinically, midostaurin’s mechanism translates into improved remission rates and survival outcomes in FLT3 mutation-positive AML when combined with standard chemotherapy. Its inhibition of KIT also underlies efficacy in systemic mastocytosis, where KIT mutations drive mast cell proliferation. Comparative studies highlight that midostaurin's multi-targeted approach offers advantages over selective FLT3 inhibitors by mitigating resistance mechanisms and addressing multiple pathogenic pathways simultaneously.

Pharmacological Actions

Inhibits FLT3 receptor tyrosine kinase activity, including both ITD and TKD mutations.
Blocks multiple kinase pathways including KIT, PDGFR, VEGFR, and protein kinase C.
Suppresses malignant cell proliferation and induces apoptosis in hematologic malignancies.
Interferes with downstream signaling pathways such as PI3K/AKT, RAS/RAF/MEK/ERK, and STAT5.
Reduces systemic mast cell proliferation in systemic mastocytosis.
Enhances chemosensitivity in acute myeloid leukemia when used with standard chemotherapy.
Active metabolites contribute to prolonged and sustained kinase inhibition.
Exerts antiangiogenic effects via VEGFR inhibition.
Modulates leukemic stem cell growth and survival mechanisms.
Impairs aberrant hematopoietic progenitor signaling to restore normal cell differentiation.

Therapeutic Or Clinical Uses

Treatment of newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutation in combination with standard induction chemotherapy with cytarabine and daunorubicin.
Consolidation therapy in AML patients post induction chemotherapy to reduce relapse risk.
Treatment of aggressive systemic mastocytosis (ASM) characterized by abnormal mast cell proliferation.
Therapy for systemic mastocytosis with associated hematological neoplasm (SM-AHN).
Management of mast cell leukemia (MCL), a rare and aggressive blood cancer involving mast cells.
Adjunct therapy to improve remission duration and overall survival in FLT3-mutated AML.
Treatment aimed at reducing leukemic cell burden and controlling disease progression in myeloid neoplasms with aberrant kinase activation.
Use in patients not eligible for stem cell transplantation to provide targeted kinase inhibition.
Prophylactic use of contraception during therapy to avoid teratogenic effects.
Monitoring and management of hematological malignancies resistant to conventional therapies via targeted therapy.

Side Or Adverse Effects

Myelosuppression leading to low blood cell counts (neutropenia, anemia, thrombocytopenia).
Gastrointestinal disturbances: nausea, vomiting, diarrhea, constipation, and stomach pain.
Infections and symptoms related to immunosuppression including fever and chills.
Injection site reactions including bruising, swelling, redness, or oozing in patients receiving concurrent injectable therapies.
Hyperglycemia manifesting as increased thirst, urination, dry mouth, and fruity breath odor.
Respiratory symptoms such as wheezing, dry cough, shortness of breath, and trouble breathing.
Mouth ulcers and sores causing oral discomfort.
Bruising and nosebleeds due to platelet reduction.
Headache and general fatigue or tiredness.
Peripheral edema presenting as swelling in hands, feet, or ankles.
Allergic reactions including hives, rash, warmth, redness, or swelling of lips, face, tongue, or throat.
Potential for secondary malignancies or treatment-related leukemias (rare and under clinical observation).
Elevated liver enzymes indicating possible hepatotoxicity.
Electrolyte imbalances requiring periodic monitoring.
Rare cardiac effects including QT prolongation, necessitating cardiac monitoring in at-risk patients.

Precautions

Ensure patients have negative pregnancy tests prior to initiation of therapy.
Effective contraception must be used by both men and women during treatment and for at least 4 months after the last dose.
Avoid breastfeeding during treatment and for at least 4 months post-therapy due to potential drug transfer via breast milk.
Monitor blood counts frequently to detect and manage myelosuppression promptly.
Assess liver function regularly because of hepatic metabolism and risk of hepatotoxicity.
Vigilant monitoring for signs of infection due to immunosuppression.
Advise patients to report respiratory symptoms early to detect pneumonitis or lung toxicity.
Patients should not crush or open capsules to ensure drug stability and efficacy.
Adjust concomitant medications that are strong CYP3A4 inhibitors or inducers to avoid altered drug levels.
Use caution in patients with pre-existing lung diseases or breathing problems.
Patient education on recognizing signs of hyperglycemia and prompt management.
Regular cardiac monitoring in patients with risk factors for QT prolongation.
Avoid abrupt discontinuation of therapy without physician guidance.
Careful evaluation before use in hepatic impairment until further data are available.
Counsel regarding potential fertility impairment and options for fertility preservation.

Warnings

Midostaurin can cause fetal harm; use effective contraception to prevent pregnancy during treatment and for 4 months after.
Risk of severe myelosuppression leading to increased susceptibility to infections and bleeding.
Not recommended for use in patients younger than 18 years old.
Severe allergic reactions including anaphylaxis may occur; immediate medical attention is required.
Potential for pulmonary toxicity necessitating close monitoring for respiratory symptoms.
Avoid use with strong CYP3A4 inhibitors which can increase midostaurin toxicity.
Risk of hyperglycemia requiring monitoring and management in susceptible patients.
Drug should not be used as a single agent induction therapy in AML; always combined with chemotherapy.
Potential hepatotoxicity requiring regular liver function tests.
Contraindicated in patients with known hypersensitivity to midostaurin or any formulation components.
Patients should not breastfeed during treatment and for 4 months thereafter due to risk to infant.
Risk of QT interval prolongation and arrhythmia in patients with cardiac risk factors.
Close monitoring recommended during first 12 weeks of therapy to detect toxicity early.
Abrupt discontinuation may impact disease control; tapering and clinical evaluation advised.
Ensure compliance with dosing schedule to maintain therapeutic plasma concentrations.

Contraindication

Known allergy or hypersensitivity to midostaurin or any ingredient of Rydapt capsules.
Pregnancy due to potential teratogenic and embryotoxic effects.
Breastfeeding during therapy and for 4 months following treatment.
Patients younger than 18 years old due to lack of safety and efficacy data.
Concurrent use of strong CYP3A4 inhibitors without appropriate dose adjustments.
Patients with severe hepatic impairment until benefit-risk assessment supports use.
Patients with uncontrolled infections or severe immunosuppression until stabilization.
Use as a single-agent induction therapy for acute myeloid leukemia is contraindicated.
Known history of severe adverse reactions to multikinase inhibitors.
Patients with baseline QT prolongation or history of significant cardiac arrhythmias without careful monitoring.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) increase midostaurin plasma concentrations and risk of toxicity.
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease midostaurin concentrations, reducing efficacy.
Concomitant use with other QT-prolonging drugs may increase risk of cardiac arrhythmias.
Interactions with anticoagulants require monitoring due to altered bleeding risk from thrombocytopenia.
Potential interaction with medications causing myelosuppression, increasing hematologic toxicity.
Coadministration with drugs affecting gastric pH may alter midostaurin absorption.
Caution advised with immunosuppressants due to compounding immunosuppressive effects.
Concurrent use with herbal supplements such as St. John's Wort can induce CYP3A4 and decrease drug levels.
Potential pharmacodynamic interactions with anti-diabetic agents due to hyperglycemia risk.
Interference with metabolizing enzymes may impact levels of concomitant chemotherapeutic agents.
Careful assessment needed when used with other multikinase inhibitors due to overlapping toxicities.
Monitoring advised when combined with corticosteroids considering immunomodulatory effects.
Avoid grapefruit and grapefruit juice which inhibit CYP3A4 and may increase midostaurin levels.
Interactions with anti-epileptics that induce hepatic enzymes may reduce midostaurin efficacy.
Adjust dose or closely monitor when coadministered with medications with narrow therapeutic indices metabolized by CYP3A4.

Preparations Of The Drug

Rydapt is supplied as oral capsules containing 25 mg of midostaurin.
Capsules are intended for oral administration only and must be swallowed whole.
Each capsule contains excipients compatible with stability and absorption; no generic formulations available as of latest update.
Packaged in moisture-resistant bottles or blister packs requiring storage at room temperature away from moisture and heat.
No intravenous or other parenteral formulations currently approved.
No modified-release or extended-release formulations; immediate-release capsules maintain consistent plasma levels.
Available under prescription with strict adherence to dosing schedules.
Requires storage in original container to protect from light and moisture.
Capsule integrity must be maintained; do not open, crush, or chew to prevent altered pharmacokinetics.
Patient education materials accompany packaging to ensure proper handling and administration.
No combination products with other antineoplastic agents; used in combination therapy under clinical supervision.
FDA-approved companion diagnostic tests recommended for identifying FLT3 mutations prior to therapy initiation.
Handling precautions advised for healthcare providers due to cytotoxic nature.
Capsules potentially hazardous if contents are exposed; protective measures recommended when handling in clinical settings.
Stability studies support shelf life when stored under recommended conditions.